Profile data is unavailable for this security.
About the company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
- Revenue in CHF (TTM)54.59m
- Net income in CHF23.09m
- Incorporated2002
- Employees22.00
- LocationNewron Pharmaceuticals SpAvia Antonio Meucci 3BRESSO 20091ItalyITA
- Phone+39 26103461
- Fax+39 261034654
- Websitehttps://www.newron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xlife Sciences AG | 839.38k | 30.75m | 122.27m | 17.00 | 5.20 | 0.4012 | 2.97 | 145.67 | 4.08 | 4.08 | 0.1284 | 52.84 | 0.0016 | -- | 0.0907 | 49,375.29 | 4.80 | 6.01 | 5.95 | 7.37 | 62.17 | 37.44 | 2,991.34 | 2,987.92 | 1.07 | -- | 0.131 | -- | -15.54 | 10.15 | 130.37 | 100.79 | -13.48 | -- |
| BioVersys AG | -100.00bn | -100.00bn | 135.67m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.28 | -- | -- | -- |
| Molecular Partners AG | 0.00 | -60.24m | 146.32m | 153.00 | -- | 1.42 | -- | -- | -1.63 | -1.63 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -45.23 | -13.09 | -49.34 | -15.66 | -- | 99.25 | -- | -56.51 | -- | -- | 0.0158 | -- | -29.38 | -24.59 | 12.81 | -- | -17.26 | -- |
| MindMaze Therapeutics Holding SA | 4.05m | -17.04m | 169.07m | 31.00 | -- | 0.4085 | -- | 41.70 | -1.36 | -1.36 | 0.3231 | 2.59 | 0.0682 | 2.49 | 2.75 | 130,774.20 | -28.66 | -33.04 | -30.87 | -35.76 | 60.24 | -- | -420.33 | -874.66 | 3.80 | -49.62 | 0.055 | -- | 39.52 | -- | 82.56 | -- | -- | -- |
| Newron Pharmaceuticals SpA | 54.59m | 23.09m | 394.29m | 22.00 | 15.84 | 272.66 | 16.96 | 7.22 | 1.24 | 1.24 | 2.83 | 0.0723 | 1.39 | -- | 11.69 | 2,481,312.00 | 58.67 | -23.70 | 123.93 | -32.05 | 98.17 | 97.14 | 42.30 | -69.33 | -- | 8.56 | 0.9708 | -- | 467.41 | 48.83 | 197.65 | -- | -23.92 | -- |
| Basilea Pharmaceutica AG Allschwil | 236.21m | 72.66m | 741.94m | 180.00 | 10.64 | 6.63 | 9.95 | 3.14 | 5.23 | 5.23 | 17.03 | 8.40 | 1.08 | 1.66 | 10.57 | 1,440,305.00 | 33.21 | 7.08 | 39.78 | 11.18 | 81.04 | 82.50 | 30.76 | 9.96 | 5.67 | 31.61 | 0.4428 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
| Kuros Biosciences AG | 87.41m | -4.66m | 981.81m | 122.00 | -- | 16.09 | -- | 11.23 | -0.122 | -0.1352 | 2.26 | 1.56 | 1.16 | 1.75 | 7.11 | 716,481.60 | -6.18 | -10.85 | -7.79 | -12.28 | 83.57 | 84.11 | -5.33 | -31.80 | 1.74 | -0.4702 | 0.0655 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| Idorsia Ltd | 232.51m | -117.94m | 984.57m | 938.00 | -- | -- | -- | 4.23 | -0.6593 | -0.6593 | 1.06 | -4.88 | 0.4807 | 0.3793 | 796.27 | -- | -24.38 | -48.63 | -53.54 | -61.12 | 86.49 | -- | -50.72 | -526.39 | 0.8345 | -6.02 | 31.03 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
Data as of Feb 16 2026. Currency figures normalised to Newron Pharmaceuticals SpA's reporting currency: Swiss Franc CHF
6.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 20 Oct 2025 | 618.15k | 3.09% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2025 | 238.25k | 1.19% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 116.44k | 0.58% |
| Valiant Bank AGas of 31 Dec 2025 | 103.77k | 0.52% |
| Pictet Asset Management SAas of 31 Oct 2025 | 65.19k | 0.33% |
| BlackRock Asset Management Deutschland AGas of 05 Feb 2026 | 57.18k | 0.29% |
| Banque Cantonale Vaudoise (Investment Management)as of 30 Sep 2025 | 41.85k | 0.21% |
| Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 30 Nov 2024 | 30.15k | 0.15% |
| Monega Kapitalanlagegesellschaft mbHas of 30 Dec 2025 | 22.00k | 0.11% |
| DWS CH AGas of 31 Oct 2025 | 21.18k | 0.11% |
More ▼
Data from 30 Dec 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
